Swedish medical technology company RaySearch Laboratories AB and Radiology Oncology Systems Inc (ROS), a US provider of radiation therapy and diagnostic imaging equipment, on Friday announced a strategic partnership aiming at identifying and pursuing opportunities involving both emerging and existing technologies, with focus on the integration of refurbished linear accelerators with advanced software solutions.
According to RaySearch and ROS, the purpose of the partnership is to jointly offer comprehensive solutions that expand access to radiation therapy, ensure high-quality care, and strengthen each party's market position. The collaboration has already resulted in several agreements.
RaySearch says that currently, many fully functional linear accelerators are routinely scrapped after 10 years, instead of being refurbished and used in centres that lack cancer treatment technology. Together, the parties says that they will work on the refurbished market, contribute to circularity, and extend the lifecycle of linear accelerators -- advancing sustainability in radiation therapy. For RaySearch, the partnership will support a wider adoption of RayStation and RayCare.
Orders have already been placed by two centres in Argentina, both equipped with Varian Trilogy linear accelerators, one centre in the USA, using TrueBeam and RayStation, and a Mexican centre using Elekta Versa HD and RayStation.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis